Market Cap (In USD)
586.95 Million
Revenue (In USD)
-
Net Income (In USD)
-54.69 Million
Avg. Volume
938.34 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.815-5.7
- PE
- -7.08
- EPS
- -0.48
- Beta Value
- 1.017
- ISIN
- US8051111016
- CUSIP
- 805111101
- CIK
- 1160308
- Shares
- 172633000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Matthew Pauls J.D., M.B.A.
- Employee Count
- -
- Website
- https://www.savarapharma.com
- Ipo Date
- 2017-04-28
- Details
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More Stocks
-
SRLZF
-
MINDACORPMinda Corporation Limited
MINDACORP
-
AVTIAvitar, Inc.
AVTI
-
CNSWF
-
DGV
-
WENAAnew Medical, Inc.
WENA
-
SRES
-
300047